Additive effects of losartan and enalapril on blood pressure and plasma active renin

Hypertension

Volumn 29, Issue 2, 1997, Pages 634-640

  Azizi, Michel ^a   Guyene, Thanh Tam ^a   Chatellier, Gilles ^a   Wargon, Mathias ^a   Ménard, Joël ^b  

^a HÔPITAL BROUSSAIS   (France)

^b INSERM   (France)

Author keywords

angiotensin II; angiotensin converting enzyme inhibitors; blood pressure; drug synergism; renin; sodium

Indexed keywords

ENALAPRIL; LOSARTAN; RENIN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; HUMAN; HYPERTENSION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031028895     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.2.634     Document Type: Article

References (20)

1. Lees KR. The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens. 1992;10(suppl 5):S3-S11.
2. Meredith PA, Donnelly R, Elliott HL, Howie CA, Reid JL. Prediction of the antihypertensive response to enalapril. J Hypertens. 1990;8: 1085-1090.
3. Juillerat L, Nussberger J, Ménard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572.
4. Van Den Meiracker AH, Man in't Veld AJ, Admiraal PJJ, Ritsema Van Eck HJ, Boomsma F, Derkx FHM, Schalekamp MADH. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803-812.
5. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
6. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.
7. Weisser K, Schloos J, Lehmann K, Dusing R, Vetter H, Mutschler E. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol. 1991;40:95-99.
8. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993;35:290-297.
9. Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci. 1988;42:1683-1688.
10. Quinn SJ, Williams GH. Regulation of aldosterone secretion. Annu Rev Physiol. 1988;50:409-426.
11. McGregor GA, Markandu ND, Smith SJ, Sagnella GA, Morton JJ. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature. 1981;291:329-331.
12. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/ MK954), in salt-deplete normal man. J Cardiovasc Pharmacol. 1993; 21:732-738.
13. Toffelmire EB, Slater K, Corvol P, Ménard J, Schambelan M. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal subjects: studies using a direct immunoradiometric assay. J Clin Invest. 1989;83:679-687.
14. Nelson E, Merill D, Sweet CS, Bradstreet T, Panebianco D, Byyny R, Herman T, Lasseter K, Levy B, Lewis G, McMahon FG, Reeves R, Ruff S, Shepherd A, Weidler D, Irvin G. Efficacy and safety of oral MK-954 (DuP753), an angiotensin receptor antagonist, in essential hypertension. J Hypertens. 1991;9(suppl 6):s468-s469. Abstract.
15. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25:1345-1350.
16. Femandez LA, Caride VJ, Strömberg C, Nävery L, Wicke JD. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol. 1994;24:937-940.
17. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
18. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Honuchi M, Pratt RE, Dzau VS. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. 1995;92:10663-10667.
19. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
20. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, Poitevin P, Samuel JL. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest. 1996;98:418-425.